Catalyst Pharmaceuticals Inc expected to post earnings of 26 cents a share - Earnings Preview

Catalyst Pharmaceuticals

06/08/2024 03:59

* Catalyst Pharmaceuticals Inc  CPRX.OQ   CPRX.O  is
expected
to show a rise in quarterly revenue when it reports  results on
August 7 for the period ending June 30 2024
    * The Coral Gables Florida-based  company is expected to
report a
12.3% increase in revenue to $111.866 million from $99.58
million a year ago, according to the mean estimate from 7
analysts, based on LSEG data. (Sales is on Total Revenue Basis.)
    * ​LSEG's mean analyst estimate for Catalyst Pharmaceuticals
Inc
is for earnings of 26 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Catalyst
Pharmaceuticals Inc is $26.00​, above​ its last closing price
of $15.49. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  0.17        0.17       0.19      Beat    14.5
 Jan. 1 2024   0.26        0.27       0.31      Beat    17
 Sep. 30 2023  -0.38       -0.28      -0.29     Missed  -1.8​
 Jun. 30 2023  0.42        0.36       0.53      Beat    48.9
 ​​Mar.        0.32        0.32       0.26      Missed  -19.3
 31 2023                                                
 Dec. 31 2022  0.23        0.21       0.22      Beat    3.8​
 Jan. 1 0001   0.19        0.19       0.20      Beat    5.3
 Jun. 30 2022  0.17        0.17       0.20      Beat    17.6
 This summary was machine generated August 6 at 02:59 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)